Can Medra’s AI-powered lab scientists finally close the feedback loop in drug discovery?
Medra raises $52M to build AI-driven lab robots that run, learn, and optimize experiments. Learn how this startup is redefining drug discovery.
Can Guardant Health and Trial Library fix the clinical trial inclusion gap with AI and genomics?
Guardant Health and Trial Library team up to improve cancer trial access using AI and genomic data. Discover how this could reshape enrollment and equity in oncology.
How GE HealthCare and Tribun Health are rethinking oncology workflows
GE HealthCare and Tribun Health join forces to unify cancer diagnostics at Sant’ Andrea Hospital. See how digital pathology is reshaping oncology workflows.
Novo Nordisk finalizes $5.2bn Akero deal to expand in advanced MASH care
Novo Nordisk has acquired Akero Therapeutics for up to $5.2 billion to advance efruxifermin, its Phase 3 MASH asset. Find out what this means for liver care.
Guardant and Gemelli bring precision oncology in-house: What it means for EU care delivery
Guardant Health brings its Guardant360 CDx test to Policlinico Gemelli in Italy. Find out how in-house liquid biopsy could reshape cancer diagnostics in Europe.
Eli Lilly’s $6bn API plant in Alabama signals new era in U.S. peptide drug manufacturing
Eli Lilly’s $6B Alabama facility will manufacture orforglipron and peptide APIs. Explore how this reshoring move could transform U.S. drug manufacturing.
Johnson & Johnson targets earlier-line myeloma with CARVYKTI expansion
Johnson & Johnson’s CARVYKTI shows 80 percent treatment-free survival at 30 months in second-line myeloma. Is CAR-T moving to earlier use?
Can Medtronic and Abbott redefine insulin delivery with the Instinct-integrated MiniMed 780G?
Medtronic’s MiniMed 780G now ships in the U.S. with Abbott’s Instinct sensor. Explore how this launch could reshape CGM-insulin system competition.
Philips launches Verida: Is AI finally delivering clinical-grade spectral CT?
Philips launches Verida, the first AI-native detector-based spectral CT. Find out how it could redefine radiology workflows and cardiac diagnostics.
Can higher-dose Wegovy reshape the obesity treatment curve for Novo Nordisk?
Novo Nordisk’s semaglutide 7.2 mg dose aims to raise Wegovy’s weight loss impact. Learn how this could shift obesity treatment and reshape clinical norms.